US, Australian scientists create blood test that detects brain cancer under an hour

In a significant medical breakthrough, scientists have developed a blood test capable of detecting brain cancer quickly and with greater accuracy than traditional methods.

This new test, termed a ‘liquid biopsy’, has been found to deliver results within an hour, offering an alternative to the more invasive surgical biopsy.

The test requires just over 100 microlitres of blood and is specifically designed to detect biomarkers related to glioblastoma, one of the most aggressive and lethal forms of brain cancer.

Researchers from the United States and Australia, led by a team at the University of Notre Dame, spearheaded the development of this cutting-edge technology.

The blood test works by sensing biomarkers known as epidermal growth factor receptors (EGFRs), which are highly effective in identifying certain types of cancers, including glioblastoma.

Its accuracy in detecting brain cancer surpasses existing methods, providing a faster and more reliable tool for early diagnosis.

This innovative approach promises to revolutionise brain cancer detection, giving doctors and patients a much-needed advantage in the fight against this deadly disease.